ZITANEO-M-500SR Tablets & ZITANEO-50
Improved Control with Better Compliance
COMPOSITION.
Sitagliptin 50mg + Metformin Hcl 500mg (SR) Tablets
INDICATION
- Diabetes type-2
- Hyperglycemia
- Insulin resistance.
- Gestational/Pre-gestational diabetes
- Diabetic neuropathy
- Insulin Adjunctive therapy
ZITANEO-M-500SR Tablets
►Sitagliptin
- Potent and highly selective hypoglycemic agent, used in the management of adults with type 2 diabetes.
- Clinical trials have demonstrated the efficacy of sitagliptin in terms of improving glycaemic control in patients with type 2 diabetes, including its use in combination with metformin.
- Demonstrates glycaemic efficacy in a broad spectrum of patients with Type 2 diabetes, including obese, elderly, and renal impaired patients and those with cardiovascular disease (CVD).
- It has a convenient once-daily oral regimen, low potential for pharmacokinetic drug-drug interactions, good efficacy, and safety profile. (Drugs 2017 Feb 770) 209-224)
Metformin (SR)
- The first-line anti-hyperglycemic agent shows excellent action in the treatment of type-2 Diabetes Mellitus.
- Is also safe and effective in the treatment of gestational diabetes and pregestational diabetes.
- Prevents diabetic neuropathy in patients and improves insulin resistance as an adjunct
- Shows exceptional drug absorption and bioavailability without any adverse effects.
- O Reduces glucose production and intestinal absorption of glucose by increasing peripheral glucose uptake
